Rethinking screening for breast cancer and prostate cancer
10.1001/jama.2009.1498 · doi-reference
Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection
10.1038/s41523-021-00267-z · doi-reference
Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort
10.1158/2767-9764.crc-22-0263 · doi-reference
The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)
10.1136/bmjopen-2018-026797 · doi-reference
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS
10.1093/jnci/djr027 · doi-reference
Epidemiology of ductal carcinoma in situ
10.1093/jncimonographs/lgq027 · doi-reference
Comparison of Mammography AI Algorithms with a Clinical Risk Model for 5-year Breast Cancer Risk Prediction: An Observational Study
10.1148/radiol.222733 · doi-reference
DEEPGEN(TM)-a novel variant calling assay for low frequency variants
10.3390/genes12040507 · doi-reference
Blood-based multi-cancer detection using a novel variant calling assay (DEEPGEN(TM)): early clinical results
10.3390/cancers13164104 · doi-reference
A review of AI-based radiomics and computational pathology approaches in triple-negative breast cancer: current applications and perspectives
10.1016/j.clbc.2023.06.004 · doi-reference
Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention
10.1126/science.abb9601 · doi-reference
Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model
10.7326/0003-4819-148-5-200803040-00004 · doi-reference
The WISDOM Study: breaking the deadlock in the breast cancer screening debate
10.1038/s41523-017-0035-5 · doi-reference
Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial
10.1093/jnci/djw290 · doi-reference
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
10.1038/ng.2563 · doi-reference
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer
10.1038/ng.3242 · doi-reference
Addressing overdiagnosis and overtreatment in cancer: a prescription for change
10.1016/s1470-2045(13)70598-9 · doi-reference
Global guidelines for breast cancer screening: A systematic review
10.1016/j.breast.2022.04.003 · doi-reference
10.1200/jco.2022.40.16_suppl.1006
10.1200/jco.2022.40.16_suppl.1006 · doi-reference
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1
10.1016/j.annonc.2020.11.011 · doi-reference
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
10.1200/jco.22.00338 · doi-reference
The current status of the clinical utility of liquid biopsies in cancer
10.1080/14737159.2019.1664290 · doi-reference
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy
10.1016/j.ccell.2023.04.008 · doi-reference
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
10.1016/j.annonc.2020.11.007 · doi-reference
Testing for ESR1 mutations to guide therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline rapid recommendation update
10.1200/jco.23.00638 · doi-reference
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
10.1016/s1470-2045(20)30444-7 · doi-reference
Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer
10.1016/j.annonc.2022.11.005 · doi-reference
Circulating tumor DNA after neoadjuvant chemotherapy in breast cancer is associated with disease relapse
10.1200/po.22.00148 · doi-reference
Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence
10.1158/1078-0432.ccr-18-3663 · doi-reference
Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer
10.1200/jco.22.00908 · doi-reference
Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer
10.1158/1078-0432.ccr-19-3005 · doi-reference
Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer
10.1126/scitranslmed.aax7392 · doi-reference
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
10.1126/scitranslmed.aab0021 · doi-reference
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer
10.1038/ncomms9760 · doi-reference
Analysis of circulating tumor DNA to monitor metastatic breast cancer
10.1056/nejmoa1213261 · doi-reference
A multi-center clinical study to harvest and characterize circulating tumor cells from patients with metastatic breast cancer using the parsortix((R)) PC1 system
10.3390/cancers14215238 · doi-reference
Circulating tumor cell transcriptomics as biopsy surrogates in metastatic breast cancer
10.1245/s10434-021-11135-2 · doi-reference
RNA-seq of circulating tumor cells in stage II-III breast cancer
10.1245/s10434-018-6540-4 · doi-reference
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
10.1056/nejmoa040766 · doi-reference
Circulating tumour cells in non-metastatic breast cancer: a prospective study
10.1016/s1470-2045(12)70209-7 · doi-reference
